ArticleFrontiers in cellular and infection microbiology2022
High prevalence of extended-spectrum beta-lactamase-producing
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and Their Newborns: A Substudy of a Randomized, Double-Blind Trial Conducted in The Gambia and Burkina Faso.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Bio-generated CoO-NPs from Salvia officinalis: a promising tool against ESBL-producing bacteria.Scientific reports · 2026Article
- Hospital Cost Components and Predictors inTropical medicine and infectious disease · 2026Article
- Prevalence, Virulence Determinants, and Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2026Article
- Molecular characterization of virulence and multidrug resistance inVeterinary world · 2026Article
- Drug Resistance Patterns and Pathogen Distribution in Patients with Urinary Tract Infection in Suzhou, China: A Five-Year Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
- Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.BMC infectious diseases · 2025Article
- The Spectrum of Bacterial Infection in a Large Cohort of Chinese Pediatric Patients with Inborn Errors of Immunity: A Nine-year, Retrospective, Single-center Study.Journal of clinical immunology · 2025Article
- Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: a 13-patient case series.BMC infectious diseases · 2025Article
- Review
- Predisposing Factors Associated with Third-Generation Cephalosporin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Dosage Regimen Optimization of Ertapenem Against ESBL-Producing Enterobacterales Infection in Critically Ill Patients Using Monte Carlo Simulation.Clinical and translational science · 2025Article
- Klebsiella pneumoniae species complex bloodstream infection in adult patients: changing epidemiology and determinants of poor outcomes.Infection · 2025Article
- Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.World journal of virology · 2025Article
- Risk of Colonization with Multidrug-Resistant Gram-Negative Bacteria Among Travellers and Migrants: A Narrative Review.Tropical medicine and infectious disease · 2025Review
- Susceptibility of various Gram-negative bacteria to antibacterial agents: SMART in China 2019-2020.BMC microbiology · 2024Article
- Phenotypic and Genotypic Profiles of Extended-Spectrum Beta-Lactamase-Producing Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDRMicroorganisms · 2023Article
- The Impact of COVID-19 Pandemic on ESBL-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Surfactant nanovesicles for augmented antibacterial activity against carbapenemase resistant enterobacteriaceae and extended spectrum beta-lactamases producing bacteria: in vitro and in vivo evaluation.BMC microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global emergence and spread of extended-spectrum beta-lactamase (ESBL)-producing Methods: This retrospective analysis was conducted from January 2016 to December 2020. A total of 384,001 clinical specimens were collected aseptically and further cultivated on an appropriate medium. All clinical isolates (one isolate per patient) were identified based on standard laboratory methods. Antibiotic susceptibility testing was performed by the Kirby Bauer disc diffusion technique following CLSI guidelines. ESBL production was screened with ceftazidime and cefotaxime discs based on the CLSI recommendations. Phenotypic confirmation of ESBL production was carried out using a double-disc synergy technique following the CLSI standard. Results: Of a total of 384,001 clinical samples analyzed for bacterial species identification, 11,065 (2.9%) tested positive for Conclusions: This study demonstrated the high prevalence and emerging antibiotic resistance of ESBL-positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.